Suffolk Capital Management LLC Sells 1,600 Shares of Loxo Oncology Inc (LOXO)

Suffolk Capital Management LLC decreased its position in Loxo Oncology Inc (NASDAQ:LOXO) by 13.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,637 shares of the biopharmaceutical company’s stock after selling 1,600 shares during the period. Suffolk Capital Management LLC’s holdings in Loxo Oncology were worth $895,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in Loxo Oncology in the 3rd quarter valued at about $122,000. Ameritas Investment Partners Inc. increased its stake in Loxo Oncology by 31.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 419 shares during the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in Loxo Oncology in the 3rd quarter valued at about $212,000. Amalgamated Bank purchased a new stake in Loxo Oncology in the 3rd quarter valued at about $268,000. Finally, Great West Life Assurance Co. Can increased its stake in Loxo Oncology by 195.8% in the 3rd quarter. Great West Life Assurance Co. Can now owns 2,958 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 1,958 shares during the last quarter.

In other news, Director Avi Z. Naider sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $100.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the director now owns 141,118 shares in the company, valued at approximately $14,111,800. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total transaction of $37,500,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,378,178 shares of company stock valued at $107,843,208. 44.40% of the stock is currently owned by company insiders.

Several equities research analysts have commented on the stock. BidaskClub upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. William Blair assumed coverage on shares of Loxo Oncology in a research note on Tuesday, November 28th. They set an “outperform” rating for the company. Citigroup decreased their price target on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. Finally, JMP Securities upgraded shares of Loxo Oncology from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $77.18 to $95.00 in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $97.33.

Shares of Loxo Oncology Inc (NASDAQ LOXO) opened at $104.80 on Friday. Loxo Oncology Inc has a one year low of $40.01 and a one year high of $108.50.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/17/suffolk-capital-management-llc-sells-1600-shares-of-loxo-oncology-inc-loxo.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply